Why It Matters

DuPont Specialty Products USA LLC has ended its lobbying relationship with Cross Potomac Consulting LLC, according to a lobbying disclosure termination filed on May 22, 2026. The LDA termination, which took effect April 3, 2026, leaves the firm without one of the country's most recognizable names in specialty chemicals and advanced materials manufacturing.

The filing itself is sparse: no specific issues are listed, no legislation is cited, and the filing amount is $0, which is standard for a termination filing closing out a prior engagement.

Cross Potomac Consulting LLC is a smaller boutique firm, and DuPont de Nemours (the parent company of DuPont Specialty Products USA LLC) is a roughly $6.85 billion revenue enterprise with a broad federal policy footprint. For a firm of Cross Potomac's size, a client of that profile typically represents meaningful revenue.

Broader Context

A Major Restructuring

The client termination lobbying filing arrives at a significant moment for DuPont. The company completed a major corporate spin-off of its Electronics & Industrial segment in late 2024, a restructuring that reshaped its business profile. What remains is a company now more heavily weighted toward healthcare packaging, water filtration, and specialty industrial materials: businesses that carry their own distinct federal policy concerns.

That kind of corporate restructuring often prompts a corresponding review of outside lobbying relationships. Priorities shift. The issues that mattered most to the old DuPont may not map cleanly onto the new DuPont's legislative agenda. That is a straightforward consequence of spinning off a major business unit.

The Policy Landscape

DuPont's federal policy concerns span several active areas of congressional and regulatory activity.

PFAS regulation remains one of the most consequential. DuPont carries significant legacy liability associated with per- and polyfluoroalkyl substances (the so-called "forever chemicals") stemming from historical use in products such as Teflon. The EPA has continued to tighten PFAS standards, and Congress has periodically weighed in through appropriations riders and standalone legislation. Any company in DuPont's position is watching those developments closely.

Chemical safety and the Toxic Substances Control Act is another perennial concern. EPA's implementation of the 2016 TSCA reforms has generated a steady stream of rulemakings affecting specialty chemical manufacturers, and the pace of that activity has not slowed.

Semiconductor and advanced manufacturing policy was a major focus for the old DuPont, given its electronics materials business. With that segment now spun off, the remaining DuPont entity has less direct exposure to CHIPS Act implementation and export control questions, though some overlap likely remains.

Trade and tariffs are newly urgent for virtually every manufacturer with global supply chains. DuPont's specialty materials business depends on inputs and customers across multiple continents, and the tariff environment of 2025 and 2026 has created real cost and planning uncertainty.

Water infrastructure is an area where DuPont's FILMTEC reverse osmosis membranes and related filtration products benefit directly from federal investment. Congressional action on water infrastructure, including funding through EPA's State Revolving Funds, is directly relevant to that business line.

No Bills Cited

The termination filing lists no legislation and no specific issues lobbied. That makes it impossible to identify specific bills that Cross Potomac worked on for DuPont, or to connect this client-termination lobbying action to any specific legislative outcome.

The Bottom Line

Without a confirmed replacement firm in the disclosure record, it's not possible to assess what outside lobbying capabilities DuPont may be adding. If and when a new registration surfaces, the relevant questions will be whether the incoming firm brings relationships on the committees that matter most to DuPont's current business. That includes the Senate Environment and Public Works Committee and House Energy and Commerce Committee on PFAS and chemical safety, the Senate Finance and House Ways and Means Committees on trade, and the appropriations subcommittees that fund EPA water programs and defense procurement.

Cross Potomac Consulting, for its part, loses a client whose parent company has the kind of federal footprint that generates sustained lobbying work over time. Whether Cross Potomac backfills that revenue with a comparable client will be worth watching in future LDA filing cycles.